drugset / Trial / NCT04316806

Effect of a Probiotic Formula on Reducing SIBO in IBS Patients

NCT04316806

Terminated 8 enrolled AB Biotics, SA
RandomizedParallel-groupSingle-blindTreatment

Summary

This randomized study evaluates the effectiveness of the a probiotic formula, compared with the antibiotic rifaximin, in the treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Irritable Bowel Syndrome (IBS) patients.

Timeline

Start
2020-11-20
Primary completion
2022-09-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 400 mg